Syngene is a Contract Research Organization that provides integrated services to the consumer goods, pharmaceutical, biotechnology, nutrition, animal health, and specialty chemicals industries across the world.
The market capitalisation of Syngene International Ltd. as on 30 August 2018 was Rs.11,820 crore.
Company's Wealth and Recent Performance
The key highlights of the company’s financial performance for the Q1 FY 2018-19, ended 31 June 2018 are as follows:
The company recorded a 38% increase in revenue which stood at Rs.425 crore, up from Rs.308 crore during the same period last year. The improvement in the quarterly performance was mainly driven by growth in Biologics Manufacturing, Discovery Services and Chemical Development Services.
The EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) stood at Rs.128 crore and reported an increase of 13% YoY.
The Profit After Tax (PAT) recorded a 6% YoY increase and stood at Rs.66 crore, up from Rs.62 crore in the same period last year.
The company re-commissioned Phase I of its S2 unit which brings on line 35,000 sq. ft. of lab space to support its future growth.
The key financial highlights of the company’s financial performance for the full FY 2017-18 and Q4 FY 2017-18, ended 31 March 2018 are as follows:
The company reported a 17% increase in revenue which stood at Rs.1,485 crore, up from Rs.1,271 crore in FY 2016-17.
EBITDA was up 10% YoY and stood at Rs.527 crore while the EBITDA margin was at Rs.35 crore.
The PAT increased by 6% and stood at Rs.305 crore, up from Rs.287.
The revenues for Q4 stood at Rs.426 crore and recorded a 35% YoY increase, from Rs.315 crore in Q4 FY 2016-17.
EBITDA for Q4 was at Rs.146 crore, up 18% while EBITDA margin was at Rs.34 crore.
The PAT for Q4 saw an increase of 8% and stood at Rs.84 crore, up from Rs.78 crore last year.
In the FY 2017-18, the company’s Chemical Development and Discovery services reported a strong growth that resulted in a good financial performance.
Syngene entered into a multi-year strategic collaboration with GSK to focus on accelerating drug discovery using its own discovery services platforms.
The company also teamed up with Merck KGaA to extend their ongoing collaboration until 2019 on various discovery research projects in the areas of Antibody Discovery, Protein Technology, Molecular Biology and others.
Syngene International Ltd. Stock Trends in 2018
The opening price of Syngene International Ltd. stock at the beginning of January 2018 on NSE was Rs.545. The scrip continued to increase throughout the month and stood at Rs.649. In the month of February and March the price of the stock was stable. The scrip increased in April and reached Rs.680.
In May, the price of the stock fell throughout the month and stood at Rs.600. The scrip decreased in the month of June and ended the month at Rs.596. In July, the stock price changed marginally and ended the month of August at Rs.592.
Syngene International Ltd. Stock Trends in 2016 and 2017
The opening price of the stock at the beginning of January 2016 on NSE was Rs.411. The scrip fell throughout the month and was down to Rs.365. The price of the stock decreased marginally in the month of February. By the end of March, the stock price stood at Rs.387. In April, the scrip picked up the pace and ended the month at Rs.390.
The price of the stock in May was stable and did not witness any major change. In June, the scrip was at Rs.407 by the end of the month. It increased by a few points in July and stood at Rs.418 towards the end. In August, the price of the stock picked up the pace and ended the month at Rs.474.
In the month of September, the stock increased further and crossed Rs.500. However, it gained strength in October and the price of the stock stood at Rs.588 by the end of the month. In November, the stock price fell towards the end of the month. The opening price of the stock by the end of November was Rs.578. In December, the scrip crossed the Rs.600 mark.
The opening price of the stock at the beginning of January 2017 on NSE was Rs.562. The scrip stood at around Rs.600 by middle of the month. In February, the stock fell by over 50 points and ended the month at Rs.502. The scrip changed marginally in the month of March and was at Rs.522. In April, the price of the stock was stable and did not change much.
The scrip fell by around 80 points in May and stood at Rs.461 by the end of the month. In June, the price of the stock was stable and did not change much. The price of the stock by the end of July was Rs.485. In August, the scrip fell by around 40 points and stood at Rs.443 by the end of the month.
The scrip crossed the Rs.500 mark in September and continued to increase in October as well. In November, the price of the stock increased by around 50 points and stood at Rs.551 by the end of the month. In December, the scrip changed marginally and was at Rs.542 by the end of the month.
Should you invest in Syngene International Ltd.?
The price of the stock has increased gradually over the past two years. It has also not witnessed any major fluctuations. The company has recorded a growth in revenue for FY 2017-18 as well as Q1 FY 2018-19.
Investing in Syngene International Ltd. stock for a long-term purpose could be a good investment option. However, it is strongly advised that you do a strong research before investing your hard-earned money in the stock market as it is risky due to its volatile nature. At the same time, you can look for mutual funds as an alternative investment option.
Syngene has served over 300 clients in the various sectors including nutrition, biotech, consumer goods and others. Incorporated in 1993, the company offers development and manufacturing services for molecular entities across consumer health, pharmaceutical, biotechnology, agrochemicals, and animal health. It has served more than 300 clients in the nutrition and consumer goods and specialty chemicals
Industries along with some of the top 10 global pharma companies.
Management of the Company
Mr. Jonathan Hunt - Chief Executive Officer (CEO)
Jonathan joined Syngene in 2015. He has been responsible in leading the company’s business operations thanks to an extensive experience spread across more than 25 years in the worldwide biopharmaceuticals industry. Before joining Syngene, Jonathan worked with Astrazeneca for more than 10 years. He was the President and Director of Astrazeneca, Austria and President & COO, Astrazeneca India. He has a BA (Business Studies & Economics) from the University of Sheffield, United Kingdom as well as an MBA has from Durham University, UK.
Mr. Manoj Nerurkar - Chief Operating Officer (COO)
Manoj has an experience of more than 20 years in the pharmaceutical development from Phase I to commercialization. He has played a crucial role in Syngene's leadership as well as operational management over past several years. Before joining Syngene, Manoj was working with Novartis and was responsible for setting up their Drug Development R&D Center in India. He has a Ph.D. in Pharmaceutical Chemistry from the University of Kansas and a degree in Business Administration from the Wharton School, University of Pennsylvania.
Listings in NSE, BSE, and Indices
The stocks of TV18 Broadcast Ltd. are available for trading on the two major stock exchanges of India - The National Stock Exchange Limited (NSE) and Bombay Stock Exchange (BSE).
Sector: Finance - Miscellaneous
The company forms a part of important indices like:
Nifty Full Midcap 100
Nifty LargeMidcap 250
Nifty Midcap 100
Nifty Midcap 150
Nifty MidSmallcap 400
S&P BSE 150 MidCap Index
S&P BSE 250 LargeMidCap Index
S&P BSE 400 MidSmallCap Index
S&P BSE 500
S&P BSE AllCap
S&P BSE Healthcare
S&P BSE MidSmallCap
S&P BSE SmallCap
Syngene International Ltd,
Biocon Park , SEZ,
Bommasandra Industrial Area - Phase-IV
Bommasandra-Jigani Link Road,
Bangalore 560 099
Stocks vs. Mutual Funds: here's what we recommend
Stock market investments require a lot of research and knowledge. They do not generally offer any tax benefits and are regarded as high-risk investments. Hence,it is crucial to have a diversified portfolio. At Bankbazaar, we encourage our readers to invest on mutual funds . It doesn't require a lot of knowledge and equity linked mutual fund schemes offer tax benefits. Additionally, since mutual funds comprise stocks from multiple companies, they help in building a diversified portfolio.
The contents of this post/blog does not constitute financial or other professional advice nor does it imply in any manner a principal-agent relationship, and is not a professional advice on a specific financial matter.